Low-grade type 1 endometrial carcinoma generally has a favorable prognosis if diagnosed in the early stage.
However, a small proportion of the patients experience recurrence, which becomes a significant clinical challenge.
Our objective was to explore the differences in tumor immune microenvironment (TIME) between recurrent and cured low-grade early-stage endometrioid carcinoma cases.
